The European Commission Grants Marketing Authorization to Bracco Imaging for Vueway (gadopiclenol) Contrast Agent in the European Union

Following the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), and the recommendation sent by EMA to the European Committee (EC), the EC has granted Marketing Authorisation to Bracco Imaging for its Vueway (gadopiclenol) contrast agent in the European Union

Related Keywords

University Of Texas ,Texas ,United States ,Vienna ,Wien ,Austria ,Houston ,America ,Fulvio Renoldi Bracco ,Max Wintermark ,Christian Herold ,European Union ,Committee For Medicinal Products Human Use ,Md Anderson Cancer Center ,European Commission ,Department Of Neuroradiology ,Drug Administration ,European Medicines Agency ,Department Of Biomedical Imaging ,Marketing Authorisation ,Medicinal Products ,Human Use ,Full Professor ,Biomedical Imaging ,Image Guided Therapy ,Medical University ,Vienna General Hospital ,Cancer Center ,Central Nervous System ,Magnetic Resonance Imaging ,Full Text View ,Body Magnetic Resonance Imaging ,Text View ,Invest Radiol ,Half Dose Gadopiclenol ,Full Dose Gadobutrol ,Contrast Enhanced Body ,Novel Drug Approvals ,Gadolinium Based Contrast ,